Q1 Earnings Forecast for Immunocore Issued By HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Analysts at HC Wainwright decreased their Q1 2027 earnings per share estimates for shares of Immunocore in a research report issued on Tuesday, November 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.17 for the quarter, down from their previous forecast of $0.18. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.04) per share. HC Wainwright also issued estimates for Immunocore’s Q2 2027 earnings at $0.26 EPS, Q4 2027 earnings at $0.52 EPS and FY2027 earnings at $1.34 EPS.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.11). Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. The business had revenue of $102.22 million for the quarter, compared to the consensus estimate of $152.09 million.

Other equities research analysts have also recently issued reports about the stock. TD Cowen upgraded shares of Immunocore to a “strong-buy” rating in a research note on Monday, August 24th. Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. JPMorgan Chase & Co. initiated coverage on shares of Immunocore in a research note on Friday, August 21st. They set an “overweight” rating and a $50.00 target price on the stock. Morgan Stanley set a $43.00 price target on shares of Immunocore in a research report on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

Immunocore Trading Up 2.0%

NASDAQ:IMCR opened at $32.38 on Wednesday. Immunocore has a 1 year low of $27.50 and a 1 year high of $40.71. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -49.81 and a beta of 0.82. The business has a fifty day moving average of $31.46 and a 200-day moving average of $31.70. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.62.

Institutional Trading of Immunocore

Several institutional investors have recently modified their holdings of IMCR. Engineers Gate Manager LP boosted its stake in Immunocore by 334.3% during the second quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock valued at $1,915,000 after buying an additional 46,435 shares in the last quarter. Braidwell LP bought a new stake in Immunocore in the second quarter worth about $16,552,000. Eversept Partners LP bought a new stake in Immunocore in the first quarter worth about $1,183,000. Public Employees Retirement System of Ohio acquired a new stake in Immunocore in the 2nd quarter valued at about $2,145,000. Finally, Stempoint Capital LP acquired a new stake in Immunocore in the 1st quarter valued at about $1,916,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Trending Headlines about Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Shares crossed above their 200-day moving average, a potentially supportive technical signal, despite the earnings miss referenced in the report. Immunocore shares cross above 200-day moving average
• Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target—about 147% above the cited $32.38 share price—though the target was reduced from $100. HC Wainwright rating and price target
• Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the available article is a slideshow and does not detail specific new clinical findings. SITC 2026 presentation slideshow
• Negative Sentiment: HC Wainwright trimmed its 2027 EPS forecasts for Q1 ($0.17 from $0.18), Q2 ($0.26 from $0.29) and full-year 2027 ($1.34 from $1.36). It raised its Q4 estimate to $0.52 from $0.49, but the overall revisions were lower.
• Negative Sentiment: The cut in HC Wainwright’s price target from $100 to $80 may weigh on sentiment, even with its Buy rating retained.

Immunocore Company Profile

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.